A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes

Hung Tsung Wu, Horng Yih Ou, Hao Chang Hung, Yu Chu Su, Feng Hwa Lu, Jin Shang Wu, Yi Ching Yang, Chao Liang Wu, Chih Jen Chang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aims/hypothesis: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure. Methods: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic–hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance. Results: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice. Conclusions/interpretation: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.

Original languageEnglish
Pages (from-to)1732-1742
Number of pages11
JournalDiabetologia
Volume59
Issue number8
DOIs
Publication statusPublished - Aug 1 2016
Externally publishedYes

Fingerprint

Fibrinogen
Type 2 Diabetes Mellitus
Insulin Resistance
Hepatocytes
Glucose Intolerance
Proteins
Fasting
Glucose
Insulin
Mitogen-Activated Protein Kinase 3
Liver
Mitogen-Activated Protein Kinase 1
Hep G2 Cells
High Fat Diet
Glucose Tolerance Test
Linear Models
Animal Models
Cross-Sectional Studies
Biomarkers
Regression Analysis

Keywords

  • Biomarker
  • Diabetes
  • Hepatocyte-derived fibrinogen-related protein 1
  • Impaired fasting glucose
  • Impaired glucose tolerance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. / Wu, Hung Tsung; Ou, Horng Yih; Hung, Hao Chang; Su, Yu Chu; Lu, Feng Hwa; Wu, Jin Shang; Yang, Yi Ching; Wu, Chao Liang; Chang, Chih Jen.

In: Diabetologia, Vol. 59, No. 8, 01.08.2016, p. 1732-1742.

Research output: Contribution to journalArticle

Wu, HT, Ou, HY, Hung, HC, Su, YC, Lu, FH, Wu, JS, Yang, YC, Wu, CL & Chang, CJ 2016, 'A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes', Diabetologia, vol. 59, no. 8, pp. 1732-1742. https://doi.org/10.1007/s00125-016-3991-7
Wu, Hung Tsung ; Ou, Horng Yih ; Hung, Hao Chang ; Su, Yu Chu ; Lu, Feng Hwa ; Wu, Jin Shang ; Yang, Yi Ching ; Wu, Chao Liang ; Chang, Chih Jen. / A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. In: Diabetologia. 2016 ; Vol. 59, No. 8. pp. 1732-1742.
@article{5148537a1ec543988f32f8cde3bdf665,
title = "A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes",
abstract = "Aims/hypothesis: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure. Methods: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic–hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance. Results: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice. Conclusions/interpretation: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.",
keywords = "Biomarker, Diabetes, Hepatocyte-derived fibrinogen-related protein 1, Impaired fasting glucose, Impaired glucose tolerance",
author = "Wu, {Hung Tsung} and Ou, {Horng Yih} and Hung, {Hao Chang} and Su, {Yu Chu} and Lu, {Feng Hwa} and Wu, {Jin Shang} and Yang, {Yi Ching} and Wu, {Chao Liang} and Chang, {Chih Jen}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00125-016-3991-7",
language = "English",
volume = "59",
pages = "1732--1742",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes

AU - Wu, Hung Tsung

AU - Ou, Horng Yih

AU - Hung, Hao Chang

AU - Su, Yu Chu

AU - Lu, Feng Hwa

AU - Wu, Jin Shang

AU - Yang, Yi Ching

AU - Wu, Chao Liang

AU - Chang, Chih Jen

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Aims/hypothesis: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure. Methods: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic–hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance. Results: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice. Conclusions/interpretation: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.

AB - Aims/hypothesis: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure. Methods: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic–hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance. Results: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice. Conclusions/interpretation: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.

KW - Biomarker

KW - Diabetes

KW - Hepatocyte-derived fibrinogen-related protein 1

KW - Impaired fasting glucose

KW - Impaired glucose tolerance

UR - http://www.scopus.com/inward/record.url?scp=84969924806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969924806&partnerID=8YFLogxK

U2 - 10.1007/s00125-016-3991-7

DO - 10.1007/s00125-016-3991-7

M3 - Article

C2 - 27221093

AN - SCOPUS:84969924806

VL - 59

SP - 1732

EP - 1742

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 8

ER -